Hepatitis C Virus: Epidemiology Report and Forecast to 2035

All the vital news, analysis, and commentary curated by our industry experts.

$9995

Buy Report

Published: June 23, 2026 Report Code: GDHCER349-26-ST

Report Overview
Table of Contents
Table
Figures

Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a).

Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs (PWID), unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a). According to the World Health Organization (WHO), an estimated 50 million people have chronic hepatitis C infection globally, with approximately one million cases occurring per year (WHO, 2025a).

Scope

The Hepatitis C Virus: Epidemiology Report and Forecast Model provide an overview of the risk factors, comorbidities, and global trends of Hepatitis C in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The report includes a 10-year epidemiology forecast for the diagnosed incident cases of acute hepatitis C and diagnosed prevalent cases of chronic hepatitis C. The diagnosed incident cases of acute hepatitis C among men and women are segmented by sex, age (three years and older), genotype (genotypes 1–6), and cases that have been treated. The diagnosed prevalent cases of chronic hepatitis C are segmented by sex, age (three years and older), genotype, cirrhosis status, coinfection (hepatitis B and HIV), and cases that have been treated. Additionally, the report provides estimated incident cases of acute hepatitis C and total prevalent cases of chronic hepatitis C.

Reasons to Buy

The Hepatitis C Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global Hepatitis C markets.

Quantify patient populations in the global Hepatitis C markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hepatitis C therapeutics in each of the markets covered.

Understand magnitude of the Hepatitis C population by age, sex, genotype, cirrhosis status, coinfection, and treated status.

Table of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Catalyst

1.2 Related reports

1.3 Upcoming reports

2 Epidemiology

2.1 Disease background

2.2 Risk factors and comorbidities

2.3 Global and historical trends

2.4 8MM forecast methodology

2.4.1 Sources

2.4.2 Forecast assumptions and methods

2.4.3 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C

2.4.4 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C by genotype, diagnosed prevalent cases of chronic hepatitis C by genotype

2.4.5 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C that have been treated

2.4.6 Forecast assumptions and methods: estimated incident cases of acute hepatitis C

2.4.7 Forecast assumptions and methods: total prevalent cases of chronic hepatitis C

2.4.8 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C

2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C by cirrhosis status

2.4.10 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C by coinfection

2.4.11 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C that have been treated

2.5 Epidemiological forecast for hepatitis C (2025–35)

2.5.1 Diagnosed incident cases of acute hepatitis C

2.5.2 Age-specific diagnosed incident cases of acute hepatitis C

2.5.3 Sex-specific diagnosed incident cases of acute hepatitis C

2.5.4 Diagnosed incident cases of acute hepatitis C by genotype

2.5.5 Diagnosed incident cases of acute hepatitis C that have been treated

2.5.6 Estimated incident cases of acute hepatitis C

2.5.7 Total prevalent cases of chronic hepatitis C

2.5.8 Age-specific total prevalent cases of chronic hepatitis C

2.5.9 Sex-specific total prevalent cases of chronic hepatitis C

2.5.10 Diagnosed prevalent cases of chronic hepatitis C

2.5.11 Age-specific diagnosed prevalent cases of chronic hepatitis C

2.5.12 Sex-specific diagnosed prevalent cases of chronic hepatitis C

2.5.13 Diagnosed prevalent cases of chronic hepatitis C by genotype

2.5.14 Diagnosed prevalent cases of chronic hepatitis C by cirrhosis status

2.5.15 Diagnosed prevalent cases of chronic hepatitis C by coinfection

2.5.16 Diagnosed prevalent cases of chronic hepatitis C that have been treated

2.6 Discussion

2.6.1 Epidemiological forecast insight

2.6.2 Limitations of the analysis

2.6.3 Strengths of the analysis

3 Appendix

3.1 Bibliography

3.2 Primary research – high-prescriber survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Vice President of Disease Intelligence and Epidemiology

3.3.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: Summary of newly added data types

Table 2: Summary of updated data types

Table 3: HCV genotypes and subtypes

Table 4: Risk factors and comorbidities for hepatitis C

Table 5: High-prescribing physicians surveyed, by country

Figures

Figure 1: 8MM, diagnosed incident cases of acute hepatitis C, men and women, N, ages ≥3 years, 2025 and 2035

Figure 2: 8MM, diagnosed prevalent cases of chronic hepatitis C, men and women, N, ages ≥3 years, 2025 and 2035

Figure 3: 8MM, diagnosed incidence of acute hepatitis C, men and women, cases per 100,000 population, ages ≥3 years, 2015–35

Figure 4: 8MM, diagnosed prevalence of chronic hepatitis C, men and women, %, ages ≥3 years, 2015–35

Figure 5: 8MM, sources used and not used to forecast the diagnosed incident cases of acute hepatitis C

Figure 6: 8MM, sources used and not used to forecast the diagnosed incident cases of acute hepatitis C by genotype, and diagnosed prevalent cases of chronic hepatitis C by genotype

Figure 7: 8MM, sources used to forecast the estimated incident cases of acute hepatitis C

Figure 8: 8MM, sources used and not used to forecast the diagnosed prevalent cases of chronic hepatitis C, and the total prevalent cases of chronic hepatitis C

Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of chronic hepatitis C by cirrhosis status

Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of chronic hepatitis C by coinfection

Figure 11: 8MM, diagnosed incident cases of acute hepatitis C, N, men and women, ages ≥3 years, 2025

Figure 12: 8MM, diagnosed incident cases of acute hepatitis C by age, N, men and women, 2025

Figure 13: 8MM, diagnosed incident cases of acute hepatitis C by sex, N, ages ≥3 years, 2025

Figure 14: 8MM, diagnosed incident cases of acute hepatitis C by genotype, N, men and women, ages ≥3 years, 2025

Figure 15: 8MM, diagnosed incident cases of acute hepatitis C that had been treated, N, men and women, ages ≥3 years, 2025

Figure 16: 8MM, estimated incident cases of acute hepatitis C, N, men and women, ages ≥3 years, 2025

Figure 17: 8MM, total prevalent cases of chronic hepatitis C, N, men and women, ages ≥3 years, 2025

Figure 18: 8MM, total prevalent cases of chronic hepatitis C by age, N, men and women, 2025

Figure 19: 8MM, total prevalent cases of chronic hepatitis C by sex, N, ≥3 years, 2025

Figure 20: 8MM, diagnosed prevalent cases of chronic hepatitis C, N, men and women, ages ≥3 years, 2025

Figure 21: 8MM, diagnosed prevalent cases of chronic hepatitis C by age, N, men and women, 2025

Figure 22: 8MM, diagnosed prevalent cases of chronic hepatitis C by sex, N, ages ≥3 years, 2025

Figure 23: 8MM, diagnosed prevalent cases of chronic hepatitis C by genotype, N, men and women, ages ≥3 years, 2025

Figure 24: 8MM, diagnosed prevalent cases of chronic hepatitis C by cirrhosis status, N, men and women, ages ≥3 years, 2025

Figure 25: 8MM, diagnosed prevalent cases of chronic hepatitis C by coinfection, N, men and women, ages ≥3 years, 2025

Figure 26: 8MM, diagnosed prevalent cases of chronic hepatitis C that have been treated, N, men and women, ages ≥3 years, 2025

Hepatitis C Virus: Epidemiology Report and Forecast to 2035 standard reports

Currency USD

Single User

$9,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Hepatitis C reports

Pharmaceuticals

New

Venture Capital Investment Trends in Pharma - Q2 2026

Pharmaceuticals

New

Merger and Acquisition Trends in Pharma - Q2 2026

Pharmaceuticals

New

Emerging Market Outsourcing Report, Q2 2026

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hepatitis C Virus: Epidemiology Report and Forecast to 2035 in real time.

Access a live Hepatitis C Virus: Epidemiology Report and Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Hepatitis C Virus: Epidemiology Report and Forecast to 2035

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports